Certain A Shares of Obio Technology Corp., Ltd. are subject to a Lock-Up Agreement Ending on 22-MAR-2023.
March 21, 2023
Share
Certain A Shares of Obio Technology (Shanghai) Corp., Ltd. are subject to a Lock-Up Agreement Ending on 22-MAR-2023. These A Shares will be under lockup for 370 days starting from 17-MAR-2022 to 22-MAR-2023.
Details:
Pan Yudong, the controlling shareholder and actual controller, and Wang Fujie, Yin Shan, Xia Qingmei, Erihe, and Yang Xinglin who act in concert other than Shanghai Ouli and Shanghai Ouchuang and actual controller, Pan Yudong, acting in concert with Shanghai Ouli Investment Management Center (Limited Partnership) and Shanghai Ochuang Enterprise Management Consulting Center (Limited Partnership) promises that within 36 months from the date when the issuer's shares are listed on the Science and Technology Innovation Board, I shall not transfer or entrust others to manage my directly and indirectly held shares issued by the issuer prior to the initial public offering of shares, nor shall I propose to The issuer to repurchase this part of the shares.
Newly-added shareholders in the last year Nanjing Jinpu New Wave Venture Capital Partnership (Limited Partnership), Shenzhen Yifeng Phase Ten Venture Capital Center (Limited Partnership), Shanghai Tanying Investment Partnership (Limited Partnership), Heze Qiaobei Gongwei Venture Capital Partnership (Limited Partnership), Suzhou Shengshan Liaoying Venture Capital Enterprise (Limited Partnership), Zhejiang Free Trade Zone Fenghang Investment Partnership (Limited Partnership), Ningbo Fushen Venture Capital Partnership (Limited Partnership), Shanghai Zhangjiang Torch Venture Capital Co., Ltd., Shanghai Leyong Investment Partnership (Limited Partnership), Shanghai Qiangang Investment Management Partnership (Limited Partnership), Shanghai Chenshan Investment Management Co., Ltd., Zhuhai Sherpa Phase I Equity Investment Partnership (Limited Partnership), Beijing Kunlun Internet Intelligent Industry Investment Fund Partnership (Limited Partnership), Shanghai Gimpo National Research and Acquisition Equity Investment Fund Partnership (Limited Partnership), Shanghai Yixing Investment Management Co., Ltd., Shanghai Artificial Intelligence Industry Equity Investment Fund Partnership (Limited Partnership), Nanjing Zhizhao No. 1 Equity Investment Partnership (Limited Partnership) and Wu Jingxing, new shareholder Linzhi Tencent Technology Co., Ltd., newly-added shareholder Chengdu Boyuan Jiayu Venture Capital Partnership (Limited Partnership) and all other shareholders promised within 12 months from the date when the issuer's shares are listed on the Science and Technology Innovation Board, I shall not transfer or entrust others to manage my directly and indirectly held shares issued by the issuer prior to the initial public offering of shares, nor shall I propose to The issuer to repurchase this part of the shares.
OBio Technology Shanghai Corp Ltd is a China-based company mainly engaged in the research and development and production of recombinant viruses for gene therapy. The Company is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The Company mainly conducts business in the European and American markets and the domestic market.